LifeMD, Inc.
For the period ended Dec 31, 2025. Filed Mar 10, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 10, 2026
LFMD$2.10-11.6%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
| December 31, 2025 | December 31, 2024 | |
|---|---|---|
| ASSETS | ||
| Current Assets | ||
| Cash | $36,786,318 | $32,651,801 |
| Accounts receivable | 9,305,277 | 10,455,813 |
| Product deposit | 320,217 | 40,763 |
| Inventory, net | 2,773,576 | 2,797,358 |
| Other current assets | 2,646,077 | 3,003,539 |
| Current assets of discontinued operations | - | 3,420,086 |
| Total Current Assets | 51,831,465 | 52,369,360 |
| Non-current Assets | ||
| Equipment, net | 2,444,717 | 1,439,573 |
| Right of use assets, net | 5,267,857 | 6,228,559 |
| Capitalized software, net | 10,604,946 | 9,305,919 |
| Intangible assets, net | 262,334 | 53,336 |
| Non-current assets of discontinued operations | - | 6,699,550 |
| Total Non-current Assets | 18,579,854 | 23,726,937 |
| Total Assets | $70,411,319 | $76,096,297 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT) | ||
| Current Liabilities | ||
| Accounts payable | $14,149,154 | $10,904,671 |
| Accrued expenses | 15,974,016 | 21,756,619 |
| Current operating lease liabilities | 642,422 | 320,082 |
| Current portion of convertible long-term debt | - | 8,444,444 |
| Deferred revenue | 10,807,773 | 17,097,854 |
| Current liabilities of discontinued operations | - | 8,876,498 |
| Total Current Liabilities | 41,573,365 | 67,400,168 |
| Long-term Liabilities | ||
| Convertible long-term debt, net | - | 9,885,057 |
| Non-current operating lease liabilities | 5,681,374 | 6,279,004 |
| Non-current liabilities of discontinued operations | - | 86,188 |
| Total Liabilities | 47,254,739 | 83,650,417 |
| Commitments and contingencies (Note 12) | - | - |
| Stockholders’ Equity (Deficit) | ||
| Series A Preferred Stock, $0.0001 par value; 1,610,000 shares authorized, 1,400,000 shares issued and outstanding, liquidation value approximately, $35.8 million as of December 31, 2025 and 2024 | 140 | 140 |
| Common Stock, $0.01 par value; 100,000,000 shares authorized, 46,760,016 and 42,293,907 shares issued, 46,656,976 and 42,190,867 outstanding as of December 31, 2025 and 2024, respectively | 467,600 | 422,939 |
| Additional paid-in capital | 251,455,616 | 230,508,339 |
| Accumulated deficit | (228,603,075) | (239,850,931) |
| Treasury stock, 103,040 shares, at cost, as of December 31, 2025 and 2024 | (163,701) | (163,701) |
| Total LifeMD, Inc. Stockholders’ Equity (Deficit) | 23,156,580 | (9,083,214) |
| Non-controlling interest of discontinued operations | - | 1,529,094 |
| Total Stockholders’ Equity (Deficit) | 23,156,580 | (7,554,120) |
| Total Liabilities and Stockholders’ Equity (Deficit) | $70,411,319 | $76,096,297 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.